The PRognostic Effect of Environmental Factors in Crohn's and Colitis
NCT ID: NCT03282903
Last Updated: 2024-05-20
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
2629 participants
Study Classification
OBSERVATIONAL
Study Start Date
2016-11-01
Study Completion Date
2022-03-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The PREdiCCt Study:
This is a major study that is now being launched. This is the first study of its kind and is specifically directed toward understanding how environmental factors and the gut microorganisms influence IBD flare and recovery. For the PREdiCCt study, the investigators hope to recruit 3100 people in remission from Crohn's disease or ulcerative colitis (illness under control) from 28 inflammatory bowel disease clinics across the UK.
The investigators hope to conduct the study in the following stages;-
1. Patients with Crohn's disease, ulcerative colitis or inflammatory bowel disease unclassified (IBDU) in clinical remission (under control) will be approached in gastroenterology clinics across the country and invited to take part in the PREdiCCt study. Alternatively they will express their interest in the study after seeing PREdiCCt promotional leaflets/posters/videos/social media.
2. Participants will attend a clinic visit for routine tests and also to complete several questionnaires with a research nurse.
3. At home over the next week participants will complete detailed questionnaires assessing their environment and diet. Participants will also collect a stool and saliva sample and send this to our laboratories (the investigators have developed easy ways of doing this reliably by post). The stool sample is to analyse the microorganisms in the participant's gut and the saliva is used to analyse their DNA. In addition to this the participants are asked to complete a 4-day weighed food diary. The food diary is sent to the University of Aberdeen for analysis.
4. Investigators will then follow patients' progress over 24 months. They will be asked to complete a short questionnaire every month with a longer questionnaire after 12 months and culminating in a final questionnaire 24 months after their initial clinic visit.
5. If a participant experiences a flare, investigators will collect an additional stool sample; but most importantly investigators will look to see how the environmental and microorganism factors recorded at the beginning differ for those that flare up versus those that don't.
What investigators hope to achieve;-
1. Finding out the environmental and dietary factors for patients to avoid because they trigger flare.
2. Finding out behaviours for patients to adopt because they bring about remission.
3. Finding out what the microorganisms that predict flare look like.
4. Gaining information which helps future studies aimed at finding better diets for IBD sufferers.
5. Developing ways of gathering information online from IBD patients about their well-being that doctors can routinely use.
The investigators have assembled expert doctors, epidemiologists, microbiologists, nutrition scientists, and bioinformaticians. These experts will use the systems the investigators have put in place to make sure PREdiCCt succeeds. It will yield a lot of new information to help sufferers right away; but the information will also help to kick start many important future studies that will bring us ever closer to a cure for Crohn's disease and ulcerative colitis.
This is a major study that is now being launched. This is the first study of its kind and is specifically directed toward understanding how environmental factors and the gut microorganisms influence IBD flare and recovery. For the PREdiCCt study, the investigators hope to recruit 3100 people in remission from Crohn's disease or ulcerative colitis (illness under control) from 28 inflammatory bowel disease clinics across the UK.
The investigators hope to conduct the study in the following stages;-
1. Patients with Crohn's disease, ulcerative colitis or inflammatory bowel disease unclassified (IBDU) in clinical remission (under control) will be approached in gastroenterology clinics across the country and invited to take part in the PREdiCCt study. Alternatively they will express their interest in the study after seeing PREdiCCt promotional leaflets/posters/videos/social media.
2. Participants will attend a clinic visit for routine tests and also to complete several questionnaires with a research nurse.
3. At home over the next week participants will complete detailed questionnaires assessing their environment and diet. Participants will also collect a stool and saliva sample and send this to our laboratories (the investigators have developed easy ways of doing this reliably by post). The stool sample is to analyse the microorganisms in the participant's gut and the saliva is used to analyse their DNA. In addition to this the participants are asked to complete a 4-day weighed food diary. The food diary is sent to the University of Aberdeen for analysis.
4. Investigators will then follow patients' progress over 24 months. They will be asked to complete a short questionnaire every month with a longer questionnaire after 12 months and culminating in a final questionnaire 24 months after their initial clinic visit.
5. If a participant experiences a flare, investigators will collect an additional stool sample; but most importantly investigators will look to see how the environmental and microorganism factors recorded at the beginning differ for those that flare up versus those that don't.
What investigators hope to achieve;-
1. Finding out the environmental and dietary factors for patients to avoid because they trigger flare.
2. Finding out behaviours for patients to adopt because they bring about remission.
3. Finding out what the microorganisms that predict flare look like.
4. Gaining information which helps future studies aimed at finding better diets for IBD sufferers.
5. Developing ways of gathering information online from IBD patients about their well-being that doctors can routinely use.
The investigators have assembled expert doctors, epidemiologists, microbiologists, nutrition scientists, and bioinformaticians. These experts will use the systems the investigators have put in place to make sure PREdiCCt succeeds. It will yield a lot of new information to help sufferers right away; but the information will also help to kick start many important future studies that will bring us ever closer to a cure for Crohn's disease and ulcerative colitis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The PRECIOUS Study: Predicting Crohn's & ColitIs Outcomes in the United States
NCT03952364
Crohn Disease
Ulcerative Colitis
IBD
+1 more
UNKNOWN
Study of Factors and Mechanisms Influencing the Effects of Treatments in Crohn's Disease
NCT04135027
Crohn Disease
UNKNOWN
Predictive Factors of ANTI-TNF Response in Luminal Crohn's Disease Complicated by Abscess
NCT02856763
CD
COMPLETED
Study to Evaluate the Epidemiology and the Characteristics "Omics" in Patients Recently Diagnosed of Inflammatory Bowel Disease in Spain
NCT03689257
Inflammatory Bowel Diseases
COMPLETED
Brain-Gut Interactions in Crohn's Disease
NCT02108938
Crohn's Disease
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background
Inflammatory bowel disease (IBD) is a common cause of chronic ill-health among young people in the UK (prevalence estimated at 1 in 200 for adults and 1 in 2000 for children, with a peak incidence in the second and third decades of life)1-2. The major forms of IBD, namely Crohn's disease (CD) and ulcerative colitis (UC), all too often confer a lifetime of unpleasant, intrusive and potentially dangerous burden of intestinal inflammation on individuals. Typical symptoms include abdominal pain, diarrhoea, weight loss, and lethargy. These adversely affect schooling, work attainment, psycho-social well-being and sexual health 3-4. IBD costs the NHS £720 million per year, based on an average per patient cost of £3,000; of which half of the costs are directly attributable to relapsing patients 5. Healthcare expenditure focus in IBD is shifting from hospitalisation and surgery to medical therapy 6. However, existing treatment modalities remain limited by lack of efficacy, unacceptable toxicity and poor patient acceptability. Major surgical intervention is frequently required (\>50% in CD; \~20% in UC), with a high risk of disease recurrence, and there is an increased risk of cancer (in CD), with the highest incidence of colon cancer observed in those patients with poorly controlled disease 7. Nevertheless, there is a wide spectrum of disease severity. Around one third of patients will follow a relatively quiescent disease course 8. Understanding who gets severe, progressive disease and why, is an urgent research priority. Accurate prediction of these patients will enable precise, tailored intervention early in the disease course. This should reduce the substantial morbidity and costs associated with IBD.
Genetics, Environment and the Microbiota and Disease Natural History.
Genetic factors play a modest role in defining disease location and extent but not disease behaviour 9-12. There is very limited evidence about the gut microbiota in disease progression, although emerging data support a potential role in treatment response. We cannot alter our genes and, despite intense interest in modifying the gut microbiota (e.g. faecal transplantation) there is only limited clinically data to support this 13-14. However, it is within our control to change what we eat and to therefore potentially modify our gut microbiota to a more favourable phenotype. Patients suspect this should be part of the answer: one of the commonest questions in the clinic is, "What should I eat?" Established clinical strategies include the use of exclusive enteral nutrition (EEN) to induce remission in CD, and a low fibre diet to alleviate obstructive symptoms in stricturing disease 15. However, beyond this there is presently very limited data to support any on-going specific dietary strategy for the vast majority of patients with IBD 16. Multiple lines of emerging evidence in animal models suggest that diets high in natural plant fibres favour an anti-inflammatory gut milieu, via alterations in the gut microbiota, measurable by short-chain fatty acid (SCFA) concentrations in stool 17. Dietary fibre may protect against the development of IBD, through several mechanisms, through its conversion to acetate, butyrate and propionate (the major SCFAs). Firstly, butyrate is the main energy source for colonocytes and is associated with the maintenance of the intestinal epithelium 18. Secondly, SCFAs have immunomodulatory roles including inhibition of the transcription factor NF-KB and are the only known ligands of G-protein-coupled receptor, GPR43, which limits the inflammatory response 19-20. Interestingly, the fermentation of fibre is dependent on gut microbiota, such as Bacteroidetes species, which are deficient in patients with IBD 21. The individual source of fibre may also be important. In the US Nurses' Health Study of 170,776 women with 3,317,425 person-years of follow-up over 26 years there were 269 incident cases of Crohn's disease diagnosed and 338 cases of ulcerative colitis 22. For the latter illness, there were no associations with either total dietary fibre intake or fibre from any specific food groups. However, for Crohn's disease the highest quintile of energy-adjusted cumulative average dietary fibre intake, namely 24.3 g/day, was associated with a 41% reduction in risk compared with the lowest quintile (hazard ratio (HR) =0.59, 95% confidence interval (CI=)=0.39-0.90). This reduction was associated with the fibre content from fruits (highest vs. lowest quintile HR=0.57, 95% CI=0.38-0.85) with no associations detected between fibre from vegetables, cereals or legumes.
These are important issues; the lack of data means patients may resort to untested and potentially harmful 'fad' diets 16. More pressingly, this is potentially a novel therapeutic approach to both induce and maintain prolonged remission. Interventional studies in cases and controls will be necessary, but first further data are required from observational epidemiological studies to inform which 'interventions' are indicated and/or justified.
Rationale for the Study
It is presently very hard to predict which IBD patients in remission will flare and when. Scant data are available to advise patients on any substantial lifestyle measure they can adopt to help prevent or retard future disease from flaring. Potential areas of direct relevance to patients are aspects of habitual diet, regular exercise, sleep and stress, including that from major life events. It is hypothesised that there are multiple factors in habitual diet that are associated with increased risk of disease flare, including reduced levels of dietary fibre, high levels of n-6 PUFAs, low levels of n-3 PUFAs and dietary emulsifiers. High levels of regular physical activity are also hypothesised to reduce the rates of disease flare. These dietary aspects and facets in concert with other lifestyle factors may contribute in part to the intestinal dysbiosis associated with flare, where the investigators anticipate seeing a reduction in microbial diversity.
The major aim of this study is to identify the environmental and gut microbiota factors that predispose to disease flare and influence disease outcomes in IBD. Further, the investigators aim to build intelligent predictive models of disease behaviour and prognosis combining phenotypic, environmental and biological data inputs of direct clinical utility.
Inflammatory bowel disease (IBD) is a common cause of chronic ill-health among young people in the UK (prevalence estimated at 1 in 200 for adults and 1 in 2000 for children, with a peak incidence in the second and third decades of life)1-2. The major forms of IBD, namely Crohn's disease (CD) and ulcerative colitis (UC), all too often confer a lifetime of unpleasant, intrusive and potentially dangerous burden of intestinal inflammation on individuals. Typical symptoms include abdominal pain, diarrhoea, weight loss, and lethargy. These adversely affect schooling, work attainment, psycho-social well-being and sexual health 3-4. IBD costs the NHS £720 million per year, based on an average per patient cost of £3,000; of which half of the costs are directly attributable to relapsing patients 5. Healthcare expenditure focus in IBD is shifting from hospitalisation and surgery to medical therapy 6. However, existing treatment modalities remain limited by lack of efficacy, unacceptable toxicity and poor patient acceptability. Major surgical intervention is frequently required (\>50% in CD; \~20% in UC), with a high risk of disease recurrence, and there is an increased risk of cancer (in CD), with the highest incidence of colon cancer observed in those patients with poorly controlled disease 7. Nevertheless, there is a wide spectrum of disease severity. Around one third of patients will follow a relatively quiescent disease course 8. Understanding who gets severe, progressive disease and why, is an urgent research priority. Accurate prediction of these patients will enable precise, tailored intervention early in the disease course. This should reduce the substantial morbidity and costs associated with IBD.
Genetics, Environment and the Microbiota and Disease Natural History.
Genetic factors play a modest role in defining disease location and extent but not disease behaviour 9-12. There is very limited evidence about the gut microbiota in disease progression, although emerging data support a potential role in treatment response. We cannot alter our genes and, despite intense interest in modifying the gut microbiota (e.g. faecal transplantation) there is only limited clinically data to support this 13-14. However, it is within our control to change what we eat and to therefore potentially modify our gut microbiota to a more favourable phenotype. Patients suspect this should be part of the answer: one of the commonest questions in the clinic is, "What should I eat?" Established clinical strategies include the use of exclusive enteral nutrition (EEN) to induce remission in CD, and a low fibre diet to alleviate obstructive symptoms in stricturing disease 15. However, beyond this there is presently very limited data to support any on-going specific dietary strategy for the vast majority of patients with IBD 16. Multiple lines of emerging evidence in animal models suggest that diets high in natural plant fibres favour an anti-inflammatory gut milieu, via alterations in the gut microbiota, measurable by short-chain fatty acid (SCFA) concentrations in stool 17. Dietary fibre may protect against the development of IBD, through several mechanisms, through its conversion to acetate, butyrate and propionate (the major SCFAs). Firstly, butyrate is the main energy source for colonocytes and is associated with the maintenance of the intestinal epithelium 18. Secondly, SCFAs have immunomodulatory roles including inhibition of the transcription factor NF-KB and are the only known ligands of G-protein-coupled receptor, GPR43, which limits the inflammatory response 19-20. Interestingly, the fermentation of fibre is dependent on gut microbiota, such as Bacteroidetes species, which are deficient in patients with IBD 21. The individual source of fibre may also be important. In the US Nurses' Health Study of 170,776 women with 3,317,425 person-years of follow-up over 26 years there were 269 incident cases of Crohn's disease diagnosed and 338 cases of ulcerative colitis 22. For the latter illness, there were no associations with either total dietary fibre intake or fibre from any specific food groups. However, for Crohn's disease the highest quintile of energy-adjusted cumulative average dietary fibre intake, namely 24.3 g/day, was associated with a 41% reduction in risk compared with the lowest quintile (hazard ratio (HR) =0.59, 95% confidence interval (CI=)=0.39-0.90). This reduction was associated with the fibre content from fruits (highest vs. lowest quintile HR=0.57, 95% CI=0.38-0.85) with no associations detected between fibre from vegetables, cereals or legumes.
These are important issues; the lack of data means patients may resort to untested and potentially harmful 'fad' diets 16. More pressingly, this is potentially a novel therapeutic approach to both induce and maintain prolonged remission. Interventional studies in cases and controls will be necessary, but first further data are required from observational epidemiological studies to inform which 'interventions' are indicated and/or justified.
Rationale for the Study
It is presently very hard to predict which IBD patients in remission will flare and when. Scant data are available to advise patients on any substantial lifestyle measure they can adopt to help prevent or retard future disease from flaring. Potential areas of direct relevance to patients are aspects of habitual diet, regular exercise, sleep and stress, including that from major life events. It is hypothesised that there are multiple factors in habitual diet that are associated with increased risk of disease flare, including reduced levels of dietary fibre, high levels of n-6 PUFAs, low levels of n-3 PUFAs and dietary emulsifiers. High levels of regular physical activity are also hypothesised to reduce the rates of disease flare. These dietary aspects and facets in concert with other lifestyle factors may contribute in part to the intestinal dysbiosis associated with flare, where the investigators anticipate seeing a reduction in microbial diversity.
The major aim of this study is to identify the environmental and gut microbiota factors that predispose to disease flare and influence disease outcomes in IBD. Further, the investigators aim to build intelligent predictive models of disease behaviour and prognosis combining phenotypic, environmental and biological data inputs of direct clinical utility.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Inflammatory Bowel Diseases
Crohn Disease
Ulcerative Colitis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Crohn's disease patients
1550 Crohn's disease patients who are symptomatically controlled.
No interventions assigned to this group
Ulcerative Colitis patients
1550 Ulcerative Colitis patients who are symptomatically controlled.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
\- Confirmed Crohn's disease or ulcerative colitis or IBDU (Lennard-Jones/Porto criteria).
Clinical remission (see definition Section 3.2 of protocol) \>6 months since diagnosis with Crohn's disease, ulcerative colitis or IBDU \>2 months since any change in therapy for Crohn's disease, ulcerative colitis or IBDU Aged six years or over at study entry Written informed consent obtained from patient or parent / guardian
Clinical remission (see definition Section 3.2 of protocol) \>6 months since diagnosis with Crohn's disease, ulcerative colitis or IBDU \>2 months since any change in therapy for Crohn's disease, ulcerative colitis or IBDU Aged six years or over at study entry Written informed consent obtained from patient or parent / guardian
Exclusion Criteria
\- Patient unwilling to take part in all aspects of the study Unable to obtain written informed consent Systemic corticosteroids (oral or intravenous) within the last two months Thiopurines / methotrexate / biologic therapy started in the preceding two months
Minimum Eligible Age
6 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Aberdeen
OTHER
Sponsor Role
collaborator
Wellcome Sanger Institute
OTHER
Sponsor Role
collaborator
NHS Lothian
OTHER_GOV
Sponsor Role
collaborator
Chief Scientist Office of the Scottish Government
OTHER_GOV
Sponsor Role
collaborator
Crohn's and Colitis in Childhood
UNKNOWN
Sponsor Role
collaborator
Cure Crohn's and Colitis
UNKNOWN
Sponsor Role
collaborator
Edinburgh and Lothain Health Fund (Lothian Health Board)
UNKNOWN
Sponsor Role
collaborator
University of Edinburgh
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Charlie Lees
Role: PRINCIPAL_INVESTIGATOR
University of Edinburgh
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aberdeen Royal Infirmary
Aberdeen, , United Kingdom
Site Status
Bronglais General Hospital
Aberystwyth, , United Kingdom
Site Status
NHS Lanarkshire
Airdrie, , United Kingdom
Site Status
Ulster Hospital
Belfast, , United Kingdom
Site Status
Bristol Royal Infirmary
Bristol, , United Kingdom
Site Status
West Suffolk NHS Foundation Trust
Bury St Edmunds, , United Kingdom
Site Status
Cambridge Addenbrooke's Hospital
Cambridge, , United Kingdom
Site Status
Glangwili General Hospital
Carmarthen, , United Kingdom
Site Status
University Hospital Coventry & Warwickshire
Coventry, , United Kingdom
Site Status
Darlington Memorial Hospital
Darlington, , United Kingdom
Site Status
Ninewells Hospital
Dundee, , United Kingdom
Site Status
Eastbourne General Hospital
Eastbourne, , United Kingdom
Site Status
Western General Hospital
Edinburgh, , United Kingdom
Site Status
Royal Hospital for Sick Children,Edinburgh
Edinburgh, , United Kingdom
Site Status
Royal Devon and Exeter Hospital
Exeter, , United Kingdom
Site Status
Queen Elizabeth Hospital
Gateshead, , United Kingdom
Site Status
Glasgow Royal Infirmary
Glasgow, , United Kingdom
Site Status
Queen Elizabeth University Hospital
Glasgow, , United Kingdom
Site Status
Royal Hospital for Children, Glasgow
Glasgow, , United Kingdom
Site Status
Withybush General Hospital
Haverfordwest, , United Kingdom
Site Status
Raigmore Hospital
Inverness, , United Kingdom
Site Status
Kettering General Hospital NHS Foundation Trust
Kettering, , United Kingdom
Site Status
Queen Elizabeth King's Lynn
Kings Lynn, , United Kingdom
Site Status
Kingston Hospital
Kingston upon Thames, , United Kingdom
Site Status
NHS Fife
Kirkcaldy, , United Kingdom
Site Status
NHS Forth Valley
Larbert, , United Kingdom
Site Status
Royal Liverpool and Broadgreen University Hospitals NHS Trust
Liverpool, , United Kingdom
Site Status
St John's Hospital
Livingston, , United Kingdom
Site Status
Guy's and St Thomas' NHS Foundation Trust
London, , United Kingdom
Site Status
Royal Free Hospital
London, , United Kingdom
Site Status
Royal London Hospital (Barts Health)
London, , United Kingdom
Site Status
Newcastle Royal Victoria Hospital
Newcastle, , United Kingdom
Site Status
Nottingham University Hospitals NHS Trust
Nottingham, , United Kingdom
Site Status
Royal Berkshire Hospital
Reading, , United Kingdom
Site Status
Salford Royal Hospital
Salford, , United Kingdom
Site Status
Sandwell and West Birmingham Hospitals NHS Trust
Sandwell, , United Kingdom
Site Status
Buckinghamshire Healthcare NHS Trust
Stoke Mandeville, , United Kingdom
Site Status
Musgrove Park Hospital
Taunton, , United Kingdom
Site Status
Pinderfield General Hospital
Wakefield, , United Kingdom
Site Status
Warrington and Halton NHS FT
Warrington, , United Kingdom
Site Status
Royal Hampshire Hospital
Winchester, , United Kingdom
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United Kingdom
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRAS183889
Identifier Type: OTHER
Identifier Source: secondary_id
16/WM/0152
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Can CT Enteroclysis Predict the Outcome of Crohn's Disease
NCT00572780
COMPLETED
Blood and Stool Molecular Biomarkers Longitudinal Detection Study in Crohn's Disease (CD) Patients
NCT03566407
TERMINATED
NA
A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
NCT03668249
COMPLETED
Immunological Characteristics of Preclinical IBD
NCT05698745
RECRUITING
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
NCT00790543
COMPLETED
A Prospective Longitudinal Study of Fecal Microbiome and Calprotectin to Predict Response to Biological Therapy in Patients With CD
NCT03994224
TERMINATED
Impact of Exclusion Diet in Addition to Anti-TNF Therapy in Crohn's Disease and Ulcerative Colitis: a Prospective, Randomized, Double-arm, Open-label Study
NCT06896305
RECRUITING
NA
Study of an Environmental Risk Factor in Crohn's Disease
NCT04960826
RECRUITING
The Role of IL-23-Responsive Immune Cell Subsets in Post-Operative Recurrence in Patients With Crohn's Disease.
NCT06006039
RECRUITING
Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets
NCT03090139
COMPLETED
Remote Monitoring of IBD
NCT05886322
UNKNOWN
Role of the Chemical Environment in the Pathogenesis of Inflammatory Bowel Disease
NCT03376230
TERMINATED
Fecal Transplant for Crohn's Disease
NCT03078803
COMPLETED
PHASE2
A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease
NCT00306215
COMPLETED
PHASE2
Corporal Composition and Gut Microbiome Modification Through Exclusion Dietary Intervention in Crohn's Disease
NCT06933264
NOT_YET_RECRUITING
NA
Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease
NCT03885713
COMPLETED
PHASE4
Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's): Implementation and Feasibility
NCT05332639
RECRUITING
NA
Decoding Personalized Nutritional, Microbiome and Host Patterns Impacting Clinical and Prognostic Features in Crohn's Disease
NCT04283864
RECRUITING
Predicting IBD Treatment Outcomes With Gut Microbiome Analysis
NCT06453720
RECRUITING
Impact of the Fecal Flora Transplantation on Crohn's Disease
NCT02097797
COMPLETED
NA
Evaluation of Therapeutic Strategy to Prevent Crohn's Disease Endoscopic poSToperatIve recurreNce Based on earlY Dosage of Faecal Calprotectin
NCT06972901
RECRUITING
NA
Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease
NCT02054533
COMPLETED
Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's Disease
NCT00102921
COMPLETED
PHASE2
Biomarkers in Inflammatory Bowel Diseases
NCT02612103
COMPLETED